tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report

Clicks: 230
ID: 154037
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a high-grade carcinoma belonging to the neuroendocrine tumors of the lung and is different from typical lung large-cell carcinoma. It represents about 3% of all pulmonary malignancies and is characterized by neuroendocrine cytologic features. The treatment usually is platinum-based chemotherapy, however the outcome remains poor. Therefore new therapeutic options are needed. Tyrosine kinase inhibitors have demonstrated greater efficacy and better tolerability than standard chemotherapy in non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations. EGFR gene mutations were also rarely identified in LCNEC. We report a patient with lung LCNEC activating EGFR mutations who showed an impressive response to gefitinib.
Reference Key
aroldi2014casetyrosine Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Francesca Aroldi;Paola Bertocchi;Fausto Meriggi;Chiara Abeni;Chiara Ogliosi;Luigina Rota;Claudia Zambelli;Claudio Bnà;Alberto Zaniboni
Journal multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015
Year 2014
DOI
10.1159/000365413
URL
http://www.karger.com/Article/FullText/365413
Keywords
tyrosine kinase inhibitors gefitinib Oncology including cancer and carcinogens tumors large-cell neuroendocrine carcinomaneoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.